Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.

Cipla, which was recently hit with a 23-page Form 483 filing from the FDA, is adding to the albuterol supply strain with a U.S. recall of six batches of the asthma med. The company's voluntary recall ...

Cipla surges 8% despite 55% profit drop as brokerages turn bullish—explore if this rally signals a buying opportunity!

Cipla Limited (BSE: 500087) (NSE: CIPLA-EQ) (hereafter referred to as 'Cipla') and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as 'Cipla'), today announced that it has received ...

Pharmaceutical major Cipla reported a 3 per cent year-on-year decline in March quarter revenue to Rs 6,541 crore, with net ...

Q4 results today: Several other companies scheduled to release their financial results include Cholamandalam Finance, Eicher ...

Cipla Q4 FY26 results show a 55% drop in net profit and margin pressure, but strong India and Africa growth support sentiment ...

Cipla is targeting growth through a mix of inorganic expansion coupled with a spree of product launches in the ongoing financial year. The pharma major is targeting 2-3 peptide asset launches in the ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore increased 10% compared to ₹1,175.46 crore in the year-ago quarter. The company's revenue from operations stood at ...

India, May 20 -- Despite global market challenges, the company's core business remained resilient, driven by strong domestic demand and rising traction in emerging markets. While the US business faced ...

India business crosses ₹12,680 crore in FY26 as Cipla expands specialty pipeline, respiratory portfolio and regulated market ...

Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...